247 related articles for article (PubMed ID: 34707863)
1. TIGIT blockade enhances NK cell activity against autologous HIV-1-infected CD4
Holder KA; Burt K; Grant MD
Clin Transl Immunology; 2021; 10(10):e1348. PubMed ID: 34707863
[TBL] [Abstract][Full Text] [Related]
2. TIGIT Blockade: A Multipronged Approach to Target the HIV Reservoir.
Holder KA; Grant MD
Front Cell Infect Microbiol; 2020; 10():175. PubMed ID: 32432050
[TBL] [Abstract][Full Text] [Related]
3. TIGIT is upregulated by HIV-1 infection and marks a highly functional adaptive and mature subset of natural killer cells.
Vendrame E; Seiler C; Ranganath T; Zhao NQ; Vergara R; Alary M; Labbé AC; Guédou F; Poudrier J; Holmes S; Roger M; Blish CA
AIDS; 2020 May; 34(6):801-813. PubMed ID: 32028328
[TBL] [Abstract][Full Text] [Related]
4. TIGIT Expression on Activated NK Cells Correlates with Greater Anti-Tumor Activity but Promotes Functional Decline upon Lung Cancer Exposure: Implications for Adoptive Cell Therapy and TIGIT-Targeted Therapies.
Hasan MF; Croom-Perez TJ; Oyer JL; Dieffenthaller TA; Robles-Carrillo LD; Eloriaga JE; Kumar S; Andersen BW; Copik AJ
Cancers (Basel); 2023 May; 15(10):. PubMed ID: 37345049
[TBL] [Abstract][Full Text] [Related]
5. Repositioning liothyronine for cancer immunotherapy by blocking the interaction of immune checkpoint TIGIT/PVR.
Zhou X; Du J; Wang H; Chen C; Jiao L; Cheng X; Zhou X; Chen S; Gou S; Zhao W; Zhai W; Chen J; Gao Y
Cell Commun Signal; 2020 Sep; 18(1):142. PubMed ID: 32894141
[TBL] [Abstract][Full Text] [Related]
6. Intrinsic Expression of Immune Checkpoint Molecule TIGIT Could Help Tumor Growth
Zhou XM; Li WQ; Wu YH; Han L; Cao XG; Yang XM; Wang HF; Zhao WS; Zhai WJ; Qi YM; Gao YF
Front Immunol; 2018; 9():2821. PubMed ID: 30555485
[TBL] [Abstract][Full Text] [Related]
7. Expression of the Inhibitory Receptor TIGIT Is Up-Regulated Specifically on NK Cells With CD226 Activating Receptor From HIV-Infected Individuals.
Yin X; Liu T; Wang Z; Ma M; Lei J; Zhang Z; Fu S; Fu Y; Hu Q; Ding H; Han X; Xu J; Shang H; Jiang Y
Front Immunol; 2018; 9():2341. PubMed ID: 30364127
[TBL] [Abstract][Full Text] [Related]
8. Weak SARS-CoV-2-specific responses of TIGIT-expressing CD8 + T cells in people living with HIV after a third dose of a SARS-CoV-2 inactivated vaccine.
Jin J; Wang X; Li Y; Yang X; Wang H; Han X; Sun J; Ma Z; Duan J; Zhang G; Huang T; Zhang T; Wu H; Zhang X; Su B
Chin Med J (Engl); 2023 Dec; 136(24):2938-2947. PubMed ID: 37963586
[TBL] [Abstract][Full Text] [Related]
9. An Fc-Competent Anti-Human TIGIT Blocking Antibody Ociperlimab (BGB-A1217) Elicits Strong Immune Responses and Potent Anti-Tumor Efficacy in Pre-Clinical Models.
Chen X; Xue L; Ding X; Zhang J; Jiang L; Liu S; Hou H; Jiang B; Cheng L; Zhu Q; Zhang L; Zhou X; Ma J; Liu Q; Li Y; Ren Z; Jiang B; Song X; Song J; Jin W; Wei M; Shen Z; Liu X; Wang L; Li K; Zhang T
Front Immunol; 2022; 13():828319. PubMed ID: 35273608
[TBL] [Abstract][Full Text] [Related]
10. T-cell immunoglobulin and ITIM domain (TIGIT) receptor/poliovirus receptor (PVR) ligand engagement suppresses interferon-γ production of natural killer cells via β-arrestin 2-mediated negative signaling.
Li M; Xia P; Du Y; Liu S; Huang G; Chen J; Zhang H; Hou N; Cheng X; Zhou L; Li P; Yang X; Fan Z
J Biol Chem; 2014 Jun; 289(25):17647-57. PubMed ID: 24817116
[TBL] [Abstract][Full Text] [Related]
11. Knockout of the inhibitory receptor TIGIT enhances the antitumor response of ex vivo expanded NK cells and prevents fratricide with therapeutic Fc-active TIGIT antibodies.
Hasan MF; Campbell AR; Croom-Perez TJ; Oyer JL; Dieffenthaller TA; Robles-Carrillo LD; Cash CA; Eloriaga JE; Kumar S; Andersen BW; Naeimi Kararoudi M; Tullius BP; Lee DA; Copik AJ
J Immunother Cancer; 2023 Dec; 11(12):. PubMed ID: 38081778
[TBL] [Abstract][Full Text] [Related]
12. DNAM-1 versus TIGIT: competitive roles in tumor immunity and inflammatory responses.
Shibuya A; Shibuya K
Int Immunol; 2021 Nov; 33(12):687-692. PubMed ID: 34694361
[TBL] [Abstract][Full Text] [Related]
13. Involvement of TIGIT in Natural Killer Cell Exhaustion and Immune Escape in Patients and Mouse Model With Liver Echinococcus multilocularis Infection.
Zhang C; Wang H; Li J; Hou X; Li L; Wang W; Shi Y; Li D; Li L; Zhao Z; Li L; Aji T; Lin R; Shao Y; Vuitton DA; Tian Z; Sun H; Wen H
Hepatology; 2021 Dec; 74(6):3376-3393. PubMed ID: 34192365
[TBL] [Abstract][Full Text] [Related]
14. Immune Exhaustion of T Cells in Alveolar Echinococcosis Patients and Its Reversal by Blocking Checkpoint Receptor TIGIT in a Murine Model.
Zhang C; Lin R; Li Z; Yang S; Bi X; Wang H; Aini A; Zhang N; Abulizi A; Sun C; Li L; Zhao Z; Qin R; Li X; Li L; Aji T; Shao Y; Vuitton DA; Tian Z; Wen H
Hepatology; 2020 Apr; 71(4):1297-1315. PubMed ID: 31410870
[TBL] [Abstract][Full Text] [Related]
15. Targeting TIGIT for cancer immunotherapy: recent advances and future directions.
Zhang P; Liu X; Gu Z; Jiang Z; Zhao S; Song Y; Yu J
Biomark Res; 2024 Jan; 12(1):7. PubMed ID: 38229100
[TBL] [Abstract][Full Text] [Related]
16. Perturbed CD8
Tauriainen J; Scharf L; Frederiksen J; Naji A; Ljunggren HG; Sönnerborg A; Lund O; Reyes-Terán G; Hecht FM; Deeks SG; Betts MR; Buggert M; Karlsson AC
Sci Rep; 2017 Jan; 7():40354. PubMed ID: 28084312
[TBL] [Abstract][Full Text] [Related]
17. Analysis of the Characteristics of TIGIT-Expressing CD3
Zhang X; Lu X; Cheung AKL; Zhang Q; Liu Z; Li Z; Yuan L; Wang R; Liu Y; Tang B; Xia H; Wu H; Zhang T; Su B
Front Immunol; 2021; 12():602492. PubMed ID: 33717085
[TBL] [Abstract][Full Text] [Related]
18. Selective loss of CD107a TIGIT+ memory HIV-1-specific CD8+ T cells in PLWH over a decade of ART.
Blanch-Lombarte O; Ouchi D; Jimenez-Moyano E; Carabelli J; Marin MA; Peña R; Pelletier A; Talla A; Sharma A; Dalmau J; Santos JR; Sékaly RP; Clotet B; Prado JG
Elife; 2023 Sep; 12():. PubMed ID: 37723971
[TBL] [Abstract][Full Text] [Related]
19. Combined Blockade of TIGIT and PD-L1 Enhances Anti-Neuroblastoma Efficacy of GD2-Directed Immunotherapy with Dinutuximab Beta.
Siebert N; Zumpe M; Schwencke CH; Biskupski S; Troschke-Meurer S; Leopold J; Zikoridse A; Lode HN
Cancers (Basel); 2023 Jun; 15(13):. PubMed ID: 37444427
[TBL] [Abstract][Full Text] [Related]
20. Adaptive NK Cells with Low TIGIT Expression Are Inherently Resistant to Myeloid-Derived Suppressor Cells.
Sarhan D; Cichocki F; Zhang B; Yingst A; Spellman SR; Cooley S; Verneris MR; Blazar BR; Miller JS
Cancer Res; 2016 Oct; 76(19):5696-5706. PubMed ID: 27503932
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]